^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + BRCA2 mutation
    Cancer:Lung Adenocarcinoma
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    World J Clin Cases
    Title:

    Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report

    Published date:
    09/06/2021
    Excerpt:
    We describe a 62-year-old male patient with a right lung adenocarcinoma who harbored an EGFR exon 19 deletion mutation. NGS revealed that the patient harbored a BRCA2 germline mutation...Therefore, the patient received olaparib combined with gefitinib and recombinant human endostatin, with a rapid and long-lasting clinical response (PFS = 13.5 mo).
    Secondary therapy:
    recombinant human endostatin
    DOI:
    10.12998/wjcc.v9.i25.7498